US20120193264A1 - Production of a biopharmaceutical product - Google Patents
Production of a biopharmaceutical product Download PDFInfo
- Publication number
- US20120193264A1 US20120193264A1 US13/499,738 US201013499738A US2012193264A1 US 20120193264 A1 US20120193264 A1 US 20120193264A1 US 201013499738 A US201013499738 A US 201013499738A US 2012193264 A1 US2012193264 A1 US 2012193264A1
- Authority
- US
- United States
- Prior art keywords
- pouch
- replacement
- support
- inherent means
- biopharmaceutical product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960000074 biopharmaceutical Drugs 0.000 title claims abstract description 122
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 37
- 230000008569 process Effects 0.000 claims abstract description 37
- 239000007788 liquid Substances 0.000 claims abstract description 28
- 239000007787 solid Substances 0.000 claims abstract description 24
- 238000011049 filling Methods 0.000 claims abstract description 15
- 239000000126 substance Substances 0.000 claims description 26
- 230000004913 activation Effects 0.000 claims description 22
- 230000004044 response Effects 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 238000004381 surface treatment Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 description 109
- 239000002699 waste material Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 5
- 239000006096 absorbing agent Substances 0.000 description 4
- 238000005273 aeration Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012190 activator Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 239000003914 blood derivative Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- -1 cellular cultures Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000005276 aerator Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/14—Bags
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/04—Filters; Permeable or porous membranes or plates, e.g. dialysis
Definitions
- the invention relates to the production of a biopharmaceutical product, and its purpose is more particularly a process for the production of a biopharmaceutical product in and with a pouch unit that is selected for this purpose, such a pouch unit being specially designed for implementing this process, such a pouch unit before the filling of contents, and such a pouch unit that is filled with the finished biopharmaceutical product, and, finally, a unit that comprises, in the first place, a pouch unit, and, in the second place, means for activation of the inherent means of support and replacement of the pouch unit.
- Biopharmaceutical product is defined as a product that is obtained from biotechnology—culture media, cellular cultures, buffer solutions, artificial nutrition liquids, blood products and derivatives of blood products—or a pharmaceutical product, or more generally a product that is designed to be used in the medical field. In the context of the invention, this biopharmaceutical product has the characteristic of being in a substantially liquid or paste form.
- Such a device first of all comprises a pouch unit that includes, in the first place, the pouch in question itself, defining an inside space that can contain the biopharmaceutical product, limited by a wall, continuous as a whole, made of a film of flexible plastic material that is airtight, and non-degradable, and that can be in direct contact by its inside face with the biopharmaceutical product, and can contain it, and, in the second place, combined with the pouch, at least one port, and, if necessary, at least one functional device such as a device for mixing, aeration, . . . .
- Such a device can next comprise, if necessary, an outside rigid container for receiving the pouch unit in its inherent inside space.
- “Production process” is defined as one or more phases of a physical-chemical-biological process during which the biopharmaceutical product is partly or completely manufactured to reach the finished state that allows its immediate use or a semi-finished state that allows a subsequent use.
- Such a phase consists in, for example, the addition of one or more components using at least one port of the pouch unit, or in a mixture, an aeration, a filtration, a reaction, a heating or a cooling (with this list not being exhaustive), using at least one suitable functional device with which the pouch unit is provided.
- “Biopharmaceutical product” is defined both as the biopharmaceutical product in the finished state and an intermediate product of the process for producing the latter.
- a pouch unit that has a pouch whose two large walls are directly joined to one another is known. Once expanded, such a pouch has a limited volume and remains relatively thin, which justifies the fact that this pouch is often called “pillow” pouch or “2D” pouch (with D meaning dimensions).
- a 3D pouch with gussets that comprises two end walls and one side wall that can be folded flat or deployed unfolded, welded to one another, with the volume then able to be at least 50 liters, up to 3,000 liters, and even more, is also known.
- Such a 3D pouch is described in the document WO00/04131 or is marketed by the company Sartorius Stedim Biotech under the trademark FLEXEL® 3D.
- the wall of the pouch performs a unique mechanical function that consists in, on the one hand, containing the substantially liquid or pasty biopharmaceutical product by absorbing the forces that result from its presence in the inside space of the pouch and its direct contact with its inside face, and, on the other hand, to support the at least one port and, if necessary, the at least one functional device.
- the production of the biopharmaceutical product in the pouch unit uses or generates one or more bodies that are functionally intrinsic to the biopharmaceutical product within the scope of its production, i.e., being part of the biopharmaceutical product or a component of the latter or used for the production of the biopharmaceutical product or generated upon this occasion.
- a body is qualified here as an incident body.
- Such an incident body is such that:
- biopharmaceutical product Being and not being “substantially” within the biopharmaceutical product means, respectively, in a very predominant and quantitatively prominent way, that the incident body is located and is not located within the biopharmaceutical product.
- Such a body is termed incident relative to the biopharmaceutical product, because it is necessary to understand that the weight and the volume of the body are low to very low and even minute relative to the weight and the volume of the biopharmaceutical product.
- Such a body is solid and small in size or liquid (including paste form); in any case, it is not gaseous.
- Solid is defined as the fact of exhibiting a certain cohesion or a certain consistency and being neither liquid nor gaseous.
- a toxin or a microorganism is part of the definition of solid.
- Small in size is defined as a dimension on the order of, or less than, or significantly less than, a millimeter, down to molecular size.
- Such a body if it is solid, is individual or broken into a number, more specially a large number, of units or pieces. This is why, even though such a body is solid, it is possible to describe a biopharmaceutical product that contains it within itself as being in a substantially liquid or paste form. Consequently, a biopharmaceutical product that is in a “substantially” liquid or paste form means, in a very predominant and quantitatively prominent way, that the biopharmaceutical product is in liquid or paste form, even when it comprises such a solid body within itself.
- Such an incident body can be varied, concerning its substance, its nature, its structure, its composition, its function, its origin, its properties, its usefulness or its harmfulness . . . . It may involve, for example, a body that falls within the final composition of the biopharmaceutical product or falls within its initial composition or active ingredients or wastes or reaction by-products or impurities or a catalyst, activator, regulator or a toxin or an antibiotic or a body that acts on one or more physical-biological-chemical conditions of the biopharmaceutical product or one or more physical-biological-chemical conditions that prevail(s) in the pouch or antibody, cells, or bacteria.
- a device for introduction or evacuation is, for example, a port that can be closed or open based on the requirements.
- “Patches” that are designed to be applied on the skin of an individual comprising one or more active substances that are released once the patch is applied to the skin for dermal or transdermal use are known. Reference can be made to, for example, the documents EP-A-0278473, U.S. Pat. No. 4,557,723, U.S. Pat. No. 4,638,043, U.S. Pat. No. 4,752,478 and US-A-2009/0142388.
- Oxygen absorbers that are designed quite specially for the packaging of food products for the purpose of limiting or preventing their oxidation and thus to allow a more significant preservation period are known.
- Such an oxygen absorber can come in the form of a packet or a pellet or a label that is introduced into the packaging beside the food product or can be included or combined with the wall of the packaging itself. It is possible to refer to, for example, the documents WO 2008/084231 and WO 2005/033676. In the same way, moisture absorbers, corrosion inhibitors, absorbers of bad odors, gas emitters, and antibacterial agents are known.
- Such devices are well suited to their own purpose but cannot be applied in the case of the production of a biopharmaceutical product, as it was defined above, in particular because the product concerned is in solid form and not in liquid or paste form, and/or because the purpose of the device is the preservation and not the production of the product, and/or because the body concerned is in gaseous form and not solid or liquid (including paste form), and/or because the device does not act directly on the product concerned but on its environment.
- the purpose of the invention is therefore to meet this requirement.
- the invention has as its object a process for the production of a biopharmaceutical product in substantially liquid or paste form by a physical-chemical-biological production process, in which:
- the solid incident body is individual or is broken into a number, more specially a large number, of units or pieces.
- the solid incident body is of a dimension on the order of, or less than, or significantly less than, a millimeter, down to molecular size.
- the pouch unit is used in such a way that the incident body is moved, in a substantial way, between the biopharmaceutical product and the inherent means of support and replacement, in the direction that goes from the first to the second or in the direction that goes from the second to the first.
- the inherent means of support and replacement is functionally active in response to the value taken on by at least one physical-biological-chemical condition of the contents of the pouch or in response to the value taken on by the variation of such a physical-biological-chemical condition or in response to a dedicated activation operation of a physical, biological, or chemical nature.
- the inherent means of support and replacement before filling with contents, is not loaded with the incident body or, in contrast, is substantially loaded with the incident body.
- the inherent means of support and replacement is not loaded with an incident body, or, in contrast, is substantially loaded with the incident body.
- the invention has as its object a pouch unit that is specially designed for the implementation of the process for the production of a biopharmaceutical product in the substantially liquid or paste form that was just described, including a pouch that defines an inside space that can contain the biopharmaceutical product during its production process, limited by a continuous wall that is flexible, airtight, and non-degradable, and that can be in direct contact by its inside surface with the biopharmaceutical product, and can contain it, and, combined with the pouch, at least one port, if necessary at least one functional device.
- the pouch unit incorporates an inherent means of support and replacement:
- the pouch unit is implemented such that the inherent means of support and replacement is in direct physical contact with the contents of the pouch and such that, with the inherent means of support and replacement being functionally active, the incident body passes substantially between one and the other of the inherent means of support and replacement and within the contents of the pouch itself and is substantially loaded on the inherent means of support and replacement when it is not or should not be substantially within the biopharmaceutical product.
- the inherent means of support and replacement consists of or comprises a membrane or a coating or a surface treatment of the wall of the pouch or at least one port or functional device, or a body of support and replacement, or a compartment of support and replacement.
- the inherent means of support and replacement is located toward the inside surface of the wall of the pouch or at least one port or functional device that forms it or integrates it.
- the inherent means of support and replacement is located on the entire surface or only a portion of the surface of a face of the pouch or at least one port or functional device that forms it or integrates it by then being either located on or distributed over this surface.
- the inherent means of support and replacement is located at least in the lower part or at least in the lower part and in the median part of the unit.
- an inherent means of support and replacement has a surface area for replacement with the contents of the pouch during the process for the production of the biopharmaceutical product that is larger than, more specially significantly larger than, more specially on the order of a multiple of, the surface area of the inside face of the wall of the pouch or at least one port or functional device that forms it or integrates it, and that is in direct contact with the contents of the pouch, in particular as a result of the composition of the inherent means of support and replacement, or the wall of the pouch or at least one port or functional device that forms it or in which it is integrated or the configuration of the inherent means of support and replacement on the wall of the pouch or at least one port or functional device that forms it or in which it is integrated.
- the pouch is a 2D pouch or a 3D pouch.
- the invention also has as its object a pouch unit before filling with contents in which, according to the embodiments, the inherent means of support and replacement is not loaded with the incident body or, in contrast, is substantially loaded with the incident body.
- the invention also has as its object a pouch unit that is filled with finished biopharmaceutical product, in which, according to the embodiments, the inherent means of support and replacement is not loaded with the incident body or, in contrast, is substantially loaded with the incident body.
- the invention also has as its object a unit that comprises, in the first place, a pouch unit as it was described in which the inherent means of support and replacement is functionally active as a consequence of a dedicated activation operation, and, in the second place, means for activation of the inherent means of support and replacement of a physical, biological or chemical nature.
- the activation means consist of the biopharmaceutical product that is in the inside space of the pouch unit and that has properties that can activate the inherent means of support and replacement.
- the activation means are located outside of the pouch unit.
- FIG. 1 is a diagrammatic perspective view of a 3D pouch with gussets that is part of a pouch unit that is specially designed for implementing a process for the production of a biopharmaceutical product in a substantially liquid or paste form according to the invention, with the pouch unit incorporating an inherent means of support and replacement, whereas during the process for the production of biopharmaceutical product, at least one incident body is used or generated and whereas the pouch unit is implemented in such a way that the inherent means of support and replacement is in direct physical contact with the contents of the pouch and in such a way that with the inherent means of support and replacement being functionally active, the incident body passes substantially between one and the other of the inherent means of support and replacement and within the contents of the pouch in such a way that the incident body is substantially loaded on the inherent means of support and replacement when it is not or should not be substantially within the biopharmaceutical product.
- FIG. 2 illustrates, on the one hand, the relative arrangement of the inherent means of support and replacement relative to the pouch unit and to the contents of the pouch, and, on the other hand, the two functions of the inherent means of support and replacement.
- FIGS. 3 to 13 are eleven views, in transverse cutaways, on a larger scale illustrating different possible embodiments of the inherent means of support and replacement that the pouch unit incorporates.
- the description refers to the definitions provided above that involve the biopharmaceutical product P, its substantially liquid or paste form, the process for the production of such a biopharmaceutical product P, a 2D pouch or a 3D pouch, the incident body C, and, for this product, the qualification of solid and small size, etc.
- a pouch unit 1 as shown in FIG. 1 is part of a device that is designed for the production of a biopharmaceutical product P, i.e., a product that is obtained from biotechnology—culture media, cellular cultures, buffer solutions, artificial nutrition liquids, blood products and derivatives of blood products—or a pharmaceutical product or more generally a product that is designed to be used in the medical field.
- a biopharmaceutical product P has the characteristic of being in a substantially liquid or paste form, being totally or at least in a very predominant and quantitatively prominent way, in liquid or paste form, even when, if necessary, it comprises within itself a solid body in a very small quantity.
- the production of the biopharmaceutical product P consists of one or more phases of a physical-chemical-biological process during which the biopharmaceutical product P is completely or partly manufactured before reaching the finished state that makes possible its direct use or a semi-finished stage that makes possible a subsequent use, such as, for example, an addition of one or more components, a mixture, an aeration, a filtration, a reaction, a heating or a cooling . . . .
- one or more incident body(ies) C is/are used or generated (which includes the case where it is used and generated).
- Such an incident body C is solid and small in size or is liquid (including paste form) and, at at least one time or stage of the production process, it is necessarily substantially within the biopharmaceutical product P while at at least one other time or stage of the production process, it is not or should not be within the biopharmaceutical product P, in that in a very predominant and quantitatively prominent way, the incident body C, respectively, is located and is not located within the biopharmaceutical product P.
- Such an incident body C has a small to very small and even minute weight and volume relative to the weight and volume of the biopharmaceutical product P.
- Such an incident body C is solid and small in size, having a certain cohesion or a certain consistency, or is liquid (including paste form), in any case not being gaseous, and having, if it is solid, a dimension on the order of, or less than, or significantly less than, a millimeter, down to molecular size, where this is understood for each unit or piece.
- incident body C if it is solid, is individual or broken into a number, more specially a large number, of units or pieces.
- Such an incident body C is varied, concerning its substance, its nature, its structure, its composition, its function, its origin, its properties, its usefulness or its harmfulness . . . . It may involve, for example, a body that falls within the final composition of the biopharmaceutical product P or falls within its initial composition or active ingredients or wastes or reaction by-products or impurities or a catalyst, activator, regulator or a toxin or an antibiotic or a body that acts on one or more physical-biological-chemical conditions of the biopharmaceutical product P or one or more physical-biological-chemical conditions that prevail(s) in the pouch or antibody, cells, or bacteria.
- the pouch unit 1 includes a pouch 2 that, according to the embodiments, is a so-called 3D pouch with gussets as shown in FIG. 1 , or a so-called 2D pouch, not shown.
- the pouch 2 defines an inside space 2 a, able to contain the contents of the pouch during the production of the biopharmaceutical product P, in particular the biopharmaceutical product P itself, during its production.
- the pouch 2 is limited by a wall 3 , continuous as a whole, made of a plastic film. It is flexible, airtight and non-degradable.
- the film that forms the wall 3 is single-material or not, single-layer or not.
- The—or each of the—constituent material(s) of the film is/are selected from among the materials that satisfy the above-mentioned requirements, as well as the mechanical strength requirements.
- the wall 3 has an outside face 3 a and an inside face 3 b. “Outside” is defined as what is not located in the pouch 2 , and “inside” is defined as what is located in the pouch 2 and limits the inside space 2 a.
- the pouch 2 can be in direct contact by its inside face 3 b with the contents of the pouch 2 , in particular the biopharmaceutical product P, and can contain it.
- the pouch 2 is arranged to support at least one port 4 , for example a port for filling and a port for emptying.
- “Port” is defined as any means of communication between the outside and the inside of the pouch 2 , which is open at one or more times or in one or more stages when the communication is desired, or, if not, is sealed.
- At least one functional device 5 such as a device for mixing, aeration, filtration, measuring (whereby this list is not exhaustive), and comprising a suitable element, such as a mixing propeller, aerator, filter, probe (whereby this list is not exhaustive), is combined in general, and if necessary, with the pouch 2 .
- a suitable element such as a mixing propeller, aerator, filter, probe (whereby this list is not exhaustive)
- Such an element is at least partly placed in the inside space 2 a of the pouch 2 .
- the at least one port 4 or functional device 5 has, in line with the wall 3 of the pouch 2 , an inside face that is located in the pouch 2 .
- the pouch unit 1 at least during the process for the production of the biopharmaceutical product P, is arranged to have a lower part 2 b, an upper part 2 c, and a median part 2 d.
- the pouch 2 comprises one or a number of ports 4 for filling in the upper part 2 c (such as the port 4 shown in FIG. 12 ) and a port 4 for emptying into the lower part 2 b, and a functional device 5 for mixing in the lower part 2 b ( FIG. 13 ).
- the pouch 2 comprises one or a number of ports 4 for filling in the upper part 2 c (such as the port 4 shown in FIG. 12 ) and a port 4 for emptying into the lower part 2 b, and a functional device 5 for mixing in the lower part 2 b ( FIG. 13 ).
- Such an embodiment does not exclude others.
- the device that is designed for the production of the biopharmaceutical product P can comprise, if necessary, an outside rigid container for receiving the pouch unit 1 in its inherent inside space.
- the pouch unit 1 incorporates an inherent means of support and replacement 6 .
- “Incorporating” means that the means 6 forms a cohesive, in particular an inseparable, unit with the pouch unit 1 .
- “Inherent” means that the functions of support and replacement that describe the means 6 belong to the latter and characterize it.
- the inherent means of support and replacement 6 is formed by or integrated in the wall 3 of the pouch 2 or in at least one port 4 or functional device 5 . In so doing, the inherent means of support and replacement 6 is able to be accessible from the inside space 2 a of the pouch 2 and in direct physical contact with the contents of the pouch 2 , in particular the biopharmaceutical product P.
- the inherent means of support and replacement 6 is arranged in such a way as to be functionally capable of being able to be loaded with an incident body C and to make possible the passage of this incident body C between one and the other of the inherent means of support and replacement 6 and within the contents of the pouch 2 .
- the means 6 is therefore able to ensure a first function that consists in being able to be loaded with the incident body C and also a second function that consists in making possible the passage of the incident body C between one and the other of the inherent means of support and replacement 6 and within the contents of the pouch 2 , in particular the biopharmaceutical product P.
- “Loaded” means that the incident body C is carried or captured by or held or located on or assimilated or adsorbed or absorbed by the inherent means of support and replacement 6 in such a way that under normal conditions and without other intervention, it cannot disseminate or be disseminated, at least substantially, outside of the inherent means of support and replacement 6 or its immediate proximity.
- Passage means that the incident body C migrates and is moved from the inherent means of support and replacement 6 or its immediate proximity to the biopharmaceutical product P or to one or more of the components of the latter, in the direction that goes from the first to the second (arrows F 1 , FIG. 2 ) or from the second to the first (arrows F 2 , FIG. 2 ). In the case where there are two (or more) incident bodies C 1 and C 2 , they can “pass” in the two directions (arrows F 3 and F 4 , FIG. 2 ).
- the inherent means of support and replacement 6 is functionally active per se, in particular permanently or as a consequence of a dedicated activation operation, in particular from a given time.
- the process for the production of the biopharmaceutical product P is such that a pouch unit 1 is used as it was described above, and the biopharmaceutical product P, not totally finished, or components of the latter, and the pouch 2 , then in particular empty, is filled by thus constituting the contents of the pouch 2 .
- the production process is implemented in and with the pouch unit 1 , and during this process, the incident body C is used or generated, or the latter is used or generated.
- the production process can consist in adding a component, for example, in finely-divided solid form—from the outside of the pouch 2 and via a port 4 —to the contents in liquid or paste form that are already in the pouch 2 for having been placed there previously and in mixing the whole by means of a functional device 5 , here a mixer.
- a functional device 5 here a mixer.
- the pouch unit 1 is totally filled, or it is only partially filled, in its lower part 2 b or at least in the lower part 2 b and in all or part of the median part 2 d.
- FIG. 2 which illustrates, on the one hand, the relative arrangement of the inherent means of support and replacement 6 relative to the pouch unit 1 and to the contents of the pouch 2 , and, on the other hand, the two functions of the inherent means of support and replacement 6
- the pouch unit 1 is used in such a way that the inherent means of support and replacement 6 that is submerged at least partially by the contents of the pouch 2 are in direct physical contact with these contents, in particular the biopharmaceutical product P, and in such a way that with the inherent means of support and replacement 6 then being functionally active, the incident body C passes directly substantially between one and the other of the inherent means of support and replacement 6 and within the contents of the pouch 2 , in particular the biopharmaceutical product P.
- the incident body C is substantially loaded on the inherent means of support and replacement 6 when it is not or should not be substantially within the biopharmaceutical product P, whereas at at least a time or stage of the production process, it is necessarily substantially within the biopharmaceutical product P.
- the incident body C is a waste that is produced within the biopharmaceutical product P during the production process, and this waste is then captured by the inherent means of support and replacement 6 by being isolated and separated from the biopharmaceutical product P.
- the incident body C is an activator of the process of the production of the biopharmaceutical product that is not present within the latter at the beginning of the process, but is found there subsequently, released by the inherent means of support and replacement 6 on which it is originally loaded.
- the inherent means of support and replacement 6 consists of, or comprises, a membrane ( FIGS. 3 , 5 , 6 , 7 , 8 ) or a coating ( FIG. 4 ) or a surface treatment ( FIG. 9 ) of the wall 3 of the pouch 2 ( FIGS. 3 to 11 ) or at least one port 4 ( FIG. 12 ) or functional device 5 ( FIG. 13 ), or a support and replacement body ( FIGS. 10 ), or a support and replacement compartment ( FIG. 11 ).
- the inherent means of support and replacement 6 is located toward the lower face 3 b of the wall 3 of the pouch 2 ( FIGS. 2 to 5 and 7 to 11 ) or at least one port 4 ( FIG. 12 ) or functional device 5 ( FIG. 13 ) that forms it or integrates it.
- This embodiment does not exclude others, whereby the inherent means of support and replacement 6 can be located toward the outside face 3 a of the wall 3 of the pouch 2 whereas it is able to be accessible from the inside space 2 a of the pouch 2 and in direct physical contact with the contents of the pouch 2 ( FIG. 6 ).
- the inherent means of support and replacement 6 is located on the entire surface of the face of the wall 3 of the pouch 2 ( FIGS. 3 to 6 , 8 and 9 ) or at least one port 4 ( FIG. 12 ) or functional device 5 ( FIG. 13 ), which forms it or integrates it.
- the inherent means of support and replacement 6 is located on one portion of the surface of the face of the wall 3 of the pouch 2 or at least one port 4 or functional device 5 that forms it or integrates it by then being either located ( FIG. 7 ) or distributed over this surface.
- the inherent means of support and replacement 6 is located in the lower part 2 b of the pouch unit 1 or in this lower part 2 b and in all or part of the median part 2 d.
- the inherent means of support and replacement 6 is located in the lower part 2 b of the pouch unit 1 or in this lower part 2 b and all or part of the median part 2 d.
- the inherent means of support and replacement 6 can be located in the upper part 2 c of the pouch unit, as is the case if it is located on a port 4 such as the port 4 that is shown in FIG. 12 .
- the inherent means of support and replacement 6 has a surface area for replacement with the contents of the pouch 2 during the process for the production of the biopharmaceutical product P that is larger than, more specially significantly larger than, more specially on the order of a multiple of, the surface area of the inside face 3 b of the wall 3 of the pouch 2 or at least one port 4 or functional device 5 that forms it or integrates it, and that is in direct contact with the contents of the pouch 2 .
- Such a larger surface area for replacement is obtained as a result of the composition of the inherent means of support and replacement 6 , or the wall 3 of the pouch 2 or at least one port 4 or functional device 5 that forms it or in which it is integrated or the configuration of the inherent means of support and replacement 6 on the wall 3 of the pouch 2 or at least one port 4 or functional device 5 that forms it or in which it is integrated ( FIGS. 8 and 9 ).
- the inherent means of support and replacement 6 is active per se, for example, because its nature makes it possible to capture or release the incident body C at any time and permanently, without requiring an action to be taken to do so.
- the inherent means of support and replacement 6 is not active per se at any time and permanently but it requires being made active as a consequence of a dedicated activation operation.
- the inherent means of support and replacement 6 is made active in response to the value taken on by at least one physical-biological-chemical condition of the biopharmaceutical product P or at least one physical-biological-chemical condition existing in the pouch 2 .
- a physical-biological-chemical condition is, for example, the temperature, the pH, the composition, the contents of a certain body, the presence of a certain microorganism . . . .
- the inherent means of support and replacement 6 is made active in response to the value not of the physical-biological-chemical condition as such, but in response to the variation of such a physical-biological-chemical condition.
- the inherent means of support and replacement 6 is made active in response to a dedicated activation operation of a physical, biological or chemical nature, such as heat, stirring . . . .
- means for activating the inherent means of support and replacement 6 of a physical, biological or chemical nature are provided that are structurally separate from the pouch unit 1 but are designed to be combined functionally with it during the activation of the inherent means of support and replacement 6 .
- these activation means consist of the biopharmaceutical product P that has properties of a physical, biological or chemical nature and that can activate the inherent means of support and replacement.
- these activation means are located outside of the pouch unit 1 or in the inside space 2 a when, for example, they consist of the biopharmaceutical product P.
- the inherent means of support and replacement 6 is formed by a layer 7 that totally and continuously coats the inside face 3 b of the film of the wall 3 or the wall 3 itself.
- the inherent means of support and replacement 6 has a surface area for replacement with the biopharmaceutical product P during its production and/or its preservation that is substantially equal to the surface area of the inside face 3 b of the pouch 2 of the pouch unit 1 .
- the inherent means of support and replacement 6 is formed by a continuous coating 8 over the entire inside face 3 b of the film of the wall 3 or the wall 3 itself.
- the inherent means of support and replacement 6 is formed by a continuous layer 9 that is sandwiched between the outside face 3 a and the inside face 3 b of the film of the wall 3 or the wall 3 itself, over the entire surface of the film, or the wall.
- the inherent means of support and replacement 6 is formed by a layer 10 that totally and continuously coats the outside face 3 a of the film of the wall 3 or the wall 3 itself, with the film of the wall 3 or the wall 3 itself then being able to allow the replacement of the incident body C, in its entire thickness, from the inside space 2 a of the pouch 2 to the outside, and vice versa.
- the inherent means of support and replacement 6 is formed by a layer 11 that forms a type of part (or “patch”) 11 that locally coats the inside face 3 b of the film of the wall 3 or the wall 3 itself.
- a single such part 11 of suitable surface and shape, located at the desired spot of the film of the wall 3 or the wall 3 itself, or several parts 11 , arranged and distributed according to a suitable distribution, can be provided.
- the inherent means of support and replacement 6 is or comprises a membrane 12 that is more or less an integral part of the film of the wall 3 or the wall 3 itself, on the inside face 3 b.
- the membrane can be folded in a more or less significant way on itself.
- the inherent means of support and replacement 6 is formed by crevices 13 or an irregular surface condition with recesses or cavities of the film of the wall 3 , obtained by particle bombardment, chemical attack, . . . .
- the inherent means of support and replacement 6 has, by the very fact of the configuration that is provided thereto, a surface area for replacement with the biopharmaceutical product P during its production that is larger than the surface area of the inside face 3 b of the pouch 2 .
- the inherent means of support and replacement 6 can have a surface area for replacement on the order of several times, and even a large number of times, the surface area of the inside face 3 b of the pouch 2 .
- the inherent means of support and replacement 6 is a solid body 14 , for example carried by the film of the wall 3 or by the wall 3 itself, over or toward the inside face 3 b.
- the inherent means of support and replacement 6 has, in itself, a surface area for replacement with the biopharmaceutical product P during its production that is larger than the surface area of the inside face 3 b of the pouch 2 .
- the means 6 can have a surface area for replacement on the order of several times, and even a large number of times, the surface area of the inside face 3 b of the pouch 2 .
- the inherent means of support and replacement 6 consists of a compartment 15 that is limited by a wall 16 that makes possible the replacement between the inside and the outside of the compartment 16 .
- the inherent means of support and replacement 6 occupies the entire surface or only a portion of the surface of the film of the wall 3 or by the wall 3 itself by being either located or distributed relative to this surface.
- the inherent means of support and replacement 6 is formed by or integrated in a port 4 , while being, as above, able to be accessible from the inside space 2 a of the pouch 2 and in direct physical contact with the contents of the pouch 2 .
- This embodiment includes the case where the inherent means of support and replacement 6 is formed by or integrated not directly in the port 4 itself, but indirectly, namely in an element for supporting the port 4 .
- the inherent means of support and replacement 6 is formed by or integrated in a functional device 5 , while being, as above, able to be accessible from the inside space 2 a of the pouch 2 and in direct physical contact with the contents of the pouch 2 .
- This embodiment includes the case where the inherent means of support and replacement 6 is formed by or integrated not directly in the functional device 5 itself, but indirectly, namely in an element for supporting the functional device 5 .
- the process for production and the pouch unit 1 can be the object of several different embodiments relative to the time when the inherent means of support and replacement 6 is loaded with the incident body C and the time when it is not loaded with the incident body C, relative to the time before the filling of the pouch 2 and once the biopharmaceutical product P is produced.
- the inherent means of support and replacement 6 is not loaded with the incident body C.
- the inherent means of support and replacement 6 is substantially loaded with the incident body C.
- the inherent means of support and replacement 6 is not loaded with the incident body C.
- the inherent means of support and replacement 6 is substantially loaded with the incident body C.
- the inherent means of support and replacement 6 is not loaded with the incident body C, and after the biopharmaceutical product P has been produced, in contrast, it is loaded with the incident body C.
- This embodiment is applied, for example, with an incident body C that is an undesirable body that does not exist at the beginning of the process for the production of the biopharmaceutical product P, but is produced during this production process and that is desired to be eliminated within the biopharmaceutical product P itself.
- the inherent means of support and replacement 6 is substantially loaded with the incident body C, and after the biopharmaceutical product P has been produced, in contrast, it is not loaded with the incident body C.
- This embodiment that is applied, for example, with a body C can then be an incident body that is necessary to the process for the production of the biopharmaceutical product P, existing at the beginning of the production process, consumed during this process, and not existing at the end.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Sustainable Development (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Clinical Laboratory Science (AREA)
- Packages (AREA)
- Basic Packing Technique (AREA)
- Bag Frames (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
- The invention relates to the production of a biopharmaceutical product, and its purpose is more particularly a process for the production of a biopharmaceutical product in and with a pouch unit that is selected for this purpose, such a pouch unit being specially designed for implementing this process, such a pouch unit before the filling of contents, and such a pouch unit that is filled with the finished biopharmaceutical product, and, finally, a unit that comprises, in the first place, a pouch unit, and, in the second place, means for activation of the inherent means of support and replacement of the pouch unit.
- “Biopharmaceutical product” is defined as a product that is obtained from biotechnology—culture media, cellular cultures, buffer solutions, artificial nutrition liquids, blood products and derivatives of blood products—or a pharmaceutical product, or more generally a product that is designed to be used in the medical field. In the context of the invention, this biopharmaceutical product has the characteristic of being in a substantially liquid or paste form.
- For the purposes of production of such a biopharmaceutical product, it is common to place it directly in a pouch that is part of a device that is designed for its production. Such a device first of all comprises a pouch unit that includes, in the first place, the pouch in question itself, defining an inside space that can contain the biopharmaceutical product, limited by a wall, continuous as a whole, made of a film of flexible plastic material that is airtight, and non-degradable, and that can be in direct contact by its inside face with the biopharmaceutical product, and can contain it, and, in the second place, combined with the pouch, at least one port, and, if necessary, at least one functional device such as a device for mixing, aeration, . . . . Such a device can next comprise, if necessary, an outside rigid container for receiving the pouch unit in its inherent inside space.
- “Production process” is defined as one or more phases of a physical-chemical-biological process during which the biopharmaceutical product is partly or completely manufactured to reach the finished state that allows its immediate use or a semi-finished state that allows a subsequent use. Such a phase consists in, for example, the addition of one or more components using at least one port of the pouch unit, or in a mixture, an aeration, a filtration, a reaction, a heating or a cooling (with this list not being exhaustive), using at least one suitable functional device with which the pouch unit is provided. “Biopharmaceutical product” is defined both as the biopharmaceutical product in the finished state and an intermediate product of the process for producing the latter.
- A pouch unit that has a pouch whose two large walls are directly joined to one another is known. Once expanded, such a pouch has a limited volume and remains relatively thin, which justifies the fact that this pouch is often called “pillow” pouch or “2D” pouch (with D meaning dimensions). A 3D pouch with gussets that comprises two end walls and one side wall that can be folded flat or deployed unfolded, welded to one another, with the volume then able to be at least 50 liters, up to 3,000 liters, and even more, is also known. Such a 3D pouch is described in the document WO00/04131 or is marketed by the company Sartorius Stedim Biotech under the trademark FLEXEL® 3D.
- With such a pouch unit, the wall of the pouch performs a unique mechanical function that consists in, on the one hand, containing the substantially liquid or pasty biopharmaceutical product by absorbing the forces that result from its presence in the inside space of the pouch and its direct contact with its inside face, and, on the other hand, to support the at least one port and, if necessary, the at least one functional device.
- The production of the biopharmaceutical product in the pouch unit uses or generates one or more bodies that are functionally intrinsic to the biopharmaceutical product within the scope of its production, i.e., being part of the biopharmaceutical product or a component of the latter or used for the production of the biopharmaceutical product or generated upon this occasion. Such a body is qualified here as an incident body.
- Such an incident body is such that:
-
- At one or more times or in one or more stages of the process for the production of the biopharmaceutical product, it is necessarily substantially within the substantially liquid or pasty biopharmaceutical product,
- And at one or more other times or in one or more other stages of the production process, it is not or should not be substantially within the biopharmaceutical product.
- Being and not being “substantially” within the biopharmaceutical product means, respectively, in a very predominant and quantitatively prominent way, that the incident body is located and is not located within the biopharmaceutical product.
- Such a body is termed incident relative to the biopharmaceutical product, because it is necessary to understand that the weight and the volume of the body are low to very low and even minute relative to the weight and the volume of the biopharmaceutical product.
- Such a body is solid and small in size or liquid (including paste form); in any case, it is not gaseous. “Solid” is defined as the fact of exhibiting a certain cohesion or a certain consistency and being neither liquid nor gaseous. A toxin or a microorganism is part of the definition of solid. “Small in size” is defined as a dimension on the order of, or less than, or significantly less than, a millimeter, down to molecular size.
- Such a body, if it is solid, is individual or broken into a number, more specially a large number, of units or pieces. This is why, even though such a body is solid, it is possible to describe a biopharmaceutical product that contains it within itself as being in a substantially liquid or paste form. Consequently, a biopharmaceutical product that is in a “substantially” liquid or paste form means, in a very predominant and quantitatively prominent way, that the biopharmaceutical product is in liquid or paste form, even when it comprises such a solid body within itself.
- Such an incident body can be varied, concerning its substance, its nature, its structure, its composition, its function, its origin, its properties, its usefulness or its harmfulness . . . . It may involve, for example, a body that falls within the final composition of the biopharmaceutical product or falls within its initial composition or active ingredients or wastes or reaction by-products or impurities or a catalyst, activator, regulator or a toxin or an antibiotic or a body that acts on one or more physical-biological-chemical conditions of the biopharmaceutical product or one or more physical-biological-chemical conditions that prevail(s) in the pouch or antibody, cells, or bacteria.
- With a pouch unit for the production of biopharmaceutical products as known today, there is an obligation to abstract such an incident body, which is not always desirable or possible, or to implement an exogenic means with the pouch unit—structural or functional—which is suitable for this body. For example, the following are provided: a stage and the device for introduction into the pouch that is filled with biopharmaceutical product—or components of such a product or else intermediate products of such a final product—of such a body such as a nutrient, antibiotic, active substances, catalyst and/or a stage and the device for evacuating the pouch that is filled with biopharmaceutical product—or components of such a product or else intermediate products of such a final product—of such a body such as an undesirable or toxic substance. Such a device for introduction or evacuation is, for example, a port that can be closed or open based on the requirements.
- “Patches” that are designed to be applied on the skin of an individual comprising one or more active substances that are released once the patch is applied to the skin for dermal or transdermal use are known. Reference can be made to, for example, the documents EP-A-0278473, U.S. Pat. No. 4,557,723, U.S. Pat. No. 4,638,043, U.S. Pat. No. 4,752,478 and US-A-2009/0142388.
- Oxygen absorbers (oxygen scavengers) that are designed quite specially for the packaging of food products for the purpose of limiting or preventing their oxidation and thus to allow a more significant preservation period are known. Such an oxygen absorber can come in the form of a packet or a pellet or a label that is introduced into the packaging beside the food product or can be included or combined with the wall of the packaging itself. It is possible to refer to, for example, the documents WO 2008/084231 and WO 2005/033676. In the same way, moisture absorbers, corrosion inhibitors, absorbers of bad odors, gas emitters, and antibacterial agents are known.
- Such devices are well suited to their own purpose but cannot be applied in the case of the production of a biopharmaceutical product, as it was defined above, in particular because the product concerned is in solid form and not in liquid or paste form, and/or because the purpose of the device is the preservation and not the production of the product, and/or because the body concerned is in gaseous form and not solid or liquid (including paste form), and/or because the device does not act directly on the product concerned but on its environment.
- In the particular case of the production of a biopharmaceutical product in liquid or paste form—and not in solid form, using a pouch unit as indicated above, involving or implementing an incident body as defined above, namely in solid form and small in size and in particular fractionated—or liquid form (including paste form) and not in gaseous form, there is consequently the need to act directly on the biopharmaceutical product—and not on its environment alone, in such a way that at one or more times or stages, the incident body is necessarily within the biopharmaceutical product itself and at one or other times or stages, it is not or should not be within the biopharmaceutical product itself.
- The purpose of the invention is therefore to meet this requirement.
- For this purpose, according to a first aspect, the invention has as its object a process for the production of a biopharmaceutical product in substantially liquid or paste form by a physical-chemical-biological production process, in which:
-
- A pouch unit is provided that includes a pouch that defines an inside space that can contain the biopharmaceutical product during its production process, and said pouch unit is limited by a continuous wall that is flexible, airtight, and non-degradable, and that can be in direct contact by its inside face with the biopharmaceutical product and can contain it, and, combined with the pouch, at least one port, and, if necessary, at least one functional device,
- The biopharmaceutical product that is not totally finished or components of the latter is/are provided, and the pouch is filled with said product or components, thus constituting the contents of the pouch,
- The process for production is implemented in and with the pouch unit, and during this process, at least one incident body that is solid and small in size or liquid that is within the biopharmaceutical product is used or generated at at least one time or stage of the production process.
- This process is such that:
-
- A pouch unit that is selected for incorporating an inherent means of support and replacement is provided:
- Formed by or integrated in the wall of the pouch or in at least one port or functional device, in such a way as to be able to be accessible from the inside space of the pouch and in direct physical contact with the contents of the pouch,
- Arranged in such a way as to be functionally able to be loaded with the incident body and to make possible the passage of the incident body between one and the other of the inherent means of support and replacement and within the contents of the pouch,
- Being functionally active per se or as a consequence of a dedicated activation operation,
- And the pouch unit is used in such a way that the inherent means of support and replacement is in direct physical contact with the contents of the pouch and in such a way that with the inherent means of support and replacement being functionally active, the incident body passes substantially between one and the other of the inherent means of support and replacement and within the contents of the pouch in such a way that the incident body is substantially loaded on the inherent means of support and replacement when it is not or should not be substantially within the biopharmaceutical product.
- A pouch unit that is selected for incorporating an inherent means of support and replacement is provided:
- According to the embodiments, the solid incident body is individual or is broken into a number, more specially a large number, of units or pieces.
- According to the embodiments, the solid incident body is of a dimension on the order of, or less than, or significantly less than, a millimeter, down to molecular size.
- According to the embodiments, the pouch unit is used in such a way that the incident body is moved, in a substantial way, between the biopharmaceutical product and the inherent means of support and replacement, in the direction that goes from the first to the second or in the direction that goes from the second to the first.
- According to one embodiment and different possible variants, the inherent means of support and replacement is functionally active in response to the value taken on by at least one physical-biological-chemical condition of the contents of the pouch or in response to the value taken on by the variation of such a physical-biological-chemical condition or in response to a dedicated activation operation of a physical, biological, or chemical nature.
- According to the embodiments, before filling with contents, the inherent means of support and replacement is not loaded with the incident body or, in contrast, is substantially loaded with the incident body.
- According to the embodiments, once the biopharmaceutical product has been produced and is in the pouch, the inherent means of support and replacement is not loaded with an incident body, or, in contrast, is substantially loaded with the incident body.
- According to a second aspect, the invention has as its object a pouch unit that is specially designed for the implementation of the process for the production of a biopharmaceutical product in the substantially liquid or paste form that was just described, including a pouch that defines an inside space that can contain the biopharmaceutical product during its production process, limited by a continuous wall that is flexible, airtight, and non-degradable, and that can be in direct contact by its inside surface with the biopharmaceutical product, and can contain it, and, combined with the pouch, at least one port, if necessary at least one functional device.
- The pouch unit incorporates an inherent means of support and replacement:
-
- Formed by or integrated in the wall of the pouch or in at least one port or functional device, in such a way as to be able to be accessible from the inside space of the pouch and in direct physical contact with the contents of the pouch,
- Arranged in such a way as to be functionally able to be loaded with the incident body and to make possible the passage of the incident body between one and the other of the inherent means of support and replacement and within the contents of the pouch itself,
- Functionally active per se or as a consequence of a dedicated activation operation.
- The pouch unit is implemented such that the inherent means of support and replacement is in direct physical contact with the contents of the pouch and such that, with the inherent means of support and replacement being functionally active, the incident body passes substantially between one and the other of the inherent means of support and replacement and within the contents of the pouch itself and is substantially loaded on the inherent means of support and replacement when it is not or should not be substantially within the biopharmaceutical product.
- According to the embodiments, the inherent means of support and replacement consists of or comprises a membrane or a coating or a surface treatment of the wall of the pouch or at least one port or functional device, or a body of support and replacement, or a compartment of support and replacement.
- According to one embodiment, the inherent means of support and replacement is located toward the inside surface of the wall of the pouch or at least one port or functional device that forms it or integrates it.
- According to the embodiments, the inherent means of support and replacement is located on the entire surface or only a portion of the surface of a face of the pouch or at least one port or functional device that forms it or integrates it by then being either located on or distributed over this surface.
- With the pouch unit having, during the process for the production of the biopharmaceutical product, a lower part, an upper part, and a median part, according to the embodiments, the inherent means of support and replacement is located at least in the lower part or at least in the lower part and in the median part of the unit.
- According to the embodiments, an inherent means of support and replacement has a surface area for replacement with the contents of the pouch during the process for the production of the biopharmaceutical product that is larger than, more specially significantly larger than, more specially on the order of a multiple of, the surface area of the inside face of the wall of the pouch or at least one port or functional device that forms it or integrates it, and that is in direct contact with the contents of the pouch, in particular as a result of the composition of the inherent means of support and replacement, or the wall of the pouch or at least one port or functional device that forms it or in which it is integrated or the configuration of the inherent means of support and replacement on the wall of the pouch or at least one port or functional device that forms it or in which it is integrated.
- According to the embodiments, the pouch is a 2D pouch or a 3D pouch.
- According to a third aspect, the invention also has as its object a pouch unit before filling with contents in which, according to the embodiments, the inherent means of support and replacement is not loaded with the incident body or, in contrast, is substantially loaded with the incident body.
- According to a fourth aspect, the invention also has as its object a pouch unit that is filled with finished biopharmaceutical product, in which, according to the embodiments, the inherent means of support and replacement is not loaded with the incident body or, in contrast, is substantially loaded with the incident body.
- According to a fifth aspect, the invention also has as its object a unit that comprises, in the first place, a pouch unit as it was described in which the inherent means of support and replacement is functionally active as a consequence of a dedicated activation operation, and, in the second place, means for activation of the inherent means of support and replacement of a physical, biological or chemical nature.
- According to one embodiment, the activation means consist of the biopharmaceutical product that is in the inside space of the pouch unit and that has properties that can activate the inherent means of support and replacement.
- According to one embodiment, the activation means are located outside of the pouch unit.
- Several embodiments of the invention will now be described using drawings, in which:
-
FIG. 1 is a diagrammatic perspective view of a 3D pouch with gussets that is part of a pouch unit that is specially designed for implementing a process for the production of a biopharmaceutical product in a substantially liquid or paste form according to the invention, with the pouch unit incorporating an inherent means of support and replacement, whereas during the process for the production of biopharmaceutical product, at least one incident body is used or generated and whereas the pouch unit is implemented in such a way that the inherent means of support and replacement is in direct physical contact with the contents of the pouch and in such a way that with the inherent means of support and replacement being functionally active, the incident body passes substantially between one and the other of the inherent means of support and replacement and within the contents of the pouch in such a way that the incident body is substantially loaded on the inherent means of support and replacement when it is not or should not be substantially within the biopharmaceutical product. -
FIG. 2 illustrates, on the one hand, the relative arrangement of the inherent means of support and replacement relative to the pouch unit and to the contents of the pouch, and, on the other hand, the two functions of the inherent means of support and replacement. -
FIGS. 3 to 13 are eleven views, in transverse cutaways, on a larger scale illustrating different possible embodiments of the inherent means of support and replacement that the pouch unit incorporates. - The description refers to the definitions provided above that involve the biopharmaceutical product P, its substantially liquid or paste form, the process for the production of such a biopharmaceutical product P, a 2D pouch or a 3D pouch, the incident body C, and, for this product, the qualification of solid and small size, etc.
- A
pouch unit 1 as shown inFIG. 1 is part of a device that is designed for the production of a biopharmaceutical product P, i.e., a product that is obtained from biotechnology—culture media, cellular cultures, buffer solutions, artificial nutrition liquids, blood products and derivatives of blood products—or a pharmaceutical product or more generally a product that is designed to be used in the medical field. Such a biopharmaceutical product P has the characteristic of being in a substantially liquid or paste form, being totally or at least in a very predominant and quantitatively prominent way, in liquid or paste form, even when, if necessary, it comprises within itself a solid body in a very small quantity. - The production of the biopharmaceutical product P consists of one or more phases of a physical-chemical-biological process during which the biopharmaceutical product P is completely or partly manufactured before reaching the finished state that makes possible its direct use or a semi-finished stage that makes possible a subsequent use, such as, for example, an addition of one or more components, a mixture, an aeration, a filtration, a reaction, a heating or a cooling . . . .
- According to one characteristic of the production process, during the course of the latter, one or more incident body(ies) C is/are used or generated (which includes the case where it is used and generated). Such an incident body C is solid and small in size or is liquid (including paste form) and, at at least one time or stage of the production process, it is necessarily substantially within the biopharmaceutical product P while at at least one other time or stage of the production process, it is not or should not be within the biopharmaceutical product P, in that in a very predominant and quantitatively prominent way, the incident body C, respectively, is located and is not located within the biopharmaceutical product P. Such an incident body C has a small to very small and even minute weight and volume relative to the weight and volume of the biopharmaceutical product P.
- Such an incident body C is solid and small in size, having a certain cohesion or a certain consistency, or is liquid (including paste form), in any case not being gaseous, and having, if it is solid, a dimension on the order of, or less than, or significantly less than, a millimeter, down to molecular size, where this is understood for each unit or piece.
- As appropriate, such an incident body C, if it is solid, is individual or broken into a number, more specially a large number, of units or pieces.
- Such an incident body C is varied, concerning its substance, its nature, its structure, its composition, its function, its origin, its properties, its usefulness or its harmfulness . . . . It may involve, for example, a body that falls within the final composition of the biopharmaceutical product P or falls within its initial composition or active ingredients or wastes or reaction by-products or impurities or a catalyst, activator, regulator or a toxin or an antibiotic or a body that acts on one or more physical-biological-chemical conditions of the biopharmaceutical product P or one or more physical-biological-chemical conditions that prevail(s) in the pouch or antibody, cells, or bacteria.
- The
pouch unit 1 includes apouch 2 that, according to the embodiments, is a so-called 3D pouch with gussets as shown inFIG. 1 , or a so-called 2D pouch, not shown. - The
pouch 2 defines aninside space 2 a, able to contain the contents of the pouch during the production of the biopharmaceutical product P, in particular the biopharmaceutical product P itself, during its production. - The
pouch 2 is limited by awall 3, continuous as a whole, made of a plastic film. It is flexible, airtight and non-degradable. The film that forms thewall 3 is single-material or not, single-layer or not. The—or each of the—constituent material(s) of the film is/are selected from among the materials that satisfy the above-mentioned requirements, as well as the mechanical strength requirements. - The
wall 3 has anoutside face 3 a and aninside face 3 b. “Outside” is defined as what is not located in thepouch 2, and “inside” is defined as what is located in thepouch 2 and limits theinside space 2 a. - The
pouch 2 can be in direct contact by itsinside face 3 b with the contents of thepouch 2, in particular the biopharmaceutical product P, and can contain it. - The
pouch 2 is arranged to support at least oneport 4, for example a port for filling and a port for emptying. “Port” is defined as any means of communication between the outside and the inside of thepouch 2, which is open at one or more times or in one or more stages when the communication is desired, or, if not, is sealed. - At least one
functional device 5, such as a device for mixing, aeration, filtration, measuring (whereby this list is not exhaustive), and comprising a suitable element, such as a mixing propeller, aerator, filter, probe (whereby this list is not exhaustive), is combined in general, and if necessary, with thepouch 2. Such an element is at least partly placed in theinside space 2 a of thepouch 2. - The at least one
port 4 orfunctional device 5 has, in line with thewall 3 of thepouch 2, an inside face that is located in thepouch 2. - The
pouch unit 1, at least during the process for the production of the biopharmaceutical product P, is arranged to have alower part 2 b, anupper part 2 c, and amedian part 2 d. - In a typical embodiment, the
pouch 2 comprises one or a number ofports 4 for filling in theupper part 2 c (such as theport 4 shown inFIG. 12 ) and aport 4 for emptying into thelower part 2 b, and afunctional device 5 for mixing in thelower part 2 b (FIG. 13 ). Such an embodiment does not exclude others. - The device that is designed for the production of the biopharmaceutical product P can comprise, if necessary, an outside rigid container for receiving the
pouch unit 1 in its inherent inside space. - The
pouch unit 1 incorporates an inherent means of support andreplacement 6. “Incorporating” means that themeans 6 forms a cohesive, in particular an inseparable, unit with thepouch unit 1. “Inherent” means that the functions of support and replacement that describe themeans 6 belong to the latter and characterize it. - The inherent means of support and
replacement 6 is formed by or integrated in thewall 3 of thepouch 2 or in at least oneport 4 orfunctional device 5. In so doing, the inherent means of support andreplacement 6 is able to be accessible from theinside space 2 a of thepouch 2 and in direct physical contact with the contents of thepouch 2, in particular the biopharmaceutical product P. - The inherent means of support and
replacement 6 is arranged in such a way as to be functionally capable of being able to be loaded with an incident body C and to make possible the passage of this incident body C between one and the other of the inherent means of support andreplacement 6 and within the contents of thepouch 2. Themeans 6 is therefore able to ensure a first function that consists in being able to be loaded with the incident body C and also a second function that consists in making possible the passage of the incident body C between one and the other of the inherent means of support andreplacement 6 and within the contents of thepouch 2, in particular the biopharmaceutical product P. - “Loaded” means that the incident body C is carried or captured by or held or located on or assimilated or adsorbed or absorbed by the inherent means of support and
replacement 6 in such a way that under normal conditions and without other intervention, it cannot disseminate or be disseminated, at least substantially, outside of the inherent means of support andreplacement 6 or its immediate proximity. - “Passage” means that the incident body C migrates and is moved from the inherent means of support and
replacement 6 or its immediate proximity to the biopharmaceutical product P or to one or more of the components of the latter, in the direction that goes from the first to the second (arrows F1,FIG. 2 ) or from the second to the first (arrows F2,FIG. 2 ). In the case where there are two (or more) incident bodies C1 and C2, they can “pass” in the two directions (arrows F3 and F4,FIG. 2 ). - The inherent means of support and
replacement 6 is functionally active per se, in particular permanently or as a consequence of a dedicated activation operation, in particular from a given time. - The process for the production of the biopharmaceutical product P is such that a
pouch unit 1 is used as it was described above, and the biopharmaceutical product P, not totally finished, or components of the latter, and thepouch 2, then in particular empty, is filled by thus constituting the contents of thepouch 2. - The production process is implemented in and with the
pouch unit 1, and during this process, the incident body C is used or generated, or the latter is used or generated. For example, with the latter's sole object being to illustrate the invention, the production process can consist in adding a component, for example, in finely-divided solid form—from the outside of thepouch 2 and via aport 4—to the contents in liquid or paste form that are already in thepouch 2 for having been placed there previously and in mixing the whole by means of afunctional device 5, here a mixer. With the process generating, for example, wastes constituting here the incident body C, it is necessary to remove them from within the biopharmaceutical product P during production. This is the dual function performed by the inherent means of support andreplacement 6 that will capture the wastes/incident body C in such a way that the finally finished biopharmaceutical product P is free thereof. - As appropriate, the
pouch unit 1 is totally filled, or it is only partially filled, in itslower part 2 b or at least in thelower part 2 b and in all or part of themedian part 2 d. - As is expressly evident from
FIG. 2 , which illustrates, on the one hand, the relative arrangement of the inherent means of support andreplacement 6 relative to thepouch unit 1 and to the contents of thepouch 2, and, on the other hand, the two functions of the inherent means of support andreplacement 6, thepouch unit 1 is used in such a way that the inherent means of support andreplacement 6 that is submerged at least partially by the contents of thepouch 2 are in direct physical contact with these contents, in particular the biopharmaceutical product P, and in such a way that with the inherent means of support andreplacement 6 then being functionally active, the incident body C passes directly substantially between one and the other of the inherent means of support andreplacement 6 and within the contents of thepouch 2, in particular the biopharmaceutical product P. - Thus, the incident body C is substantially loaded on the inherent means of support and
replacement 6 when it is not or should not be substantially within the biopharmaceutical product P, whereas at at least a time or stage of the production process, it is necessarily substantially within the biopharmaceutical product P. - For example, the incident body C is a waste that is produced within the biopharmaceutical product P during the production process, and this waste is then captured by the inherent means of support and
replacement 6 by being isolated and separated from the biopharmaceutical product P. Or, conversely, the incident body C is an activator of the process of the production of the biopharmaceutical product that is not present within the latter at the beginning of the process, but is found there subsequently, released by the inherent means of support andreplacement 6 on which it is originally loaded. - According to the embodiments, the inherent means of support and
replacement 6 consists of, or comprises, a membrane (FIGS. 3 , 5, 6, 7, 8) or a coating (FIG. 4 ) or a surface treatment (FIG. 9 ) of thewall 3 of the pouch 2 (FIGS. 3 to 11 ) or at least one port 4 (FIG. 12 ) or functional device 5 (FIG. 13 ), or a support and replacement body (FIGS. 10 ), or a support and replacement compartment (FIG. 11 ). - According to one embodiment, the inherent means of support and
replacement 6 is located toward thelower face 3 b of thewall 3 of the pouch 2 (FIGS. 2 to 5 and 7 to 11) or at least one port 4 (FIG. 12 ) or functional device 5 (FIG. 13 ) that forms it or integrates it. This embodiment does not exclude others, whereby the inherent means of support andreplacement 6 can be located toward theoutside face 3 a of thewall 3 of thepouch 2 whereas it is able to be accessible from theinside space 2 a of thepouch 2 and in direct physical contact with the contents of the pouch 2 (FIG. 6 ). - According to one embodiment, the inherent means of support and
replacement 6 is located on the entire surface of the face of thewall 3 of the pouch 2 (FIGS. 3 to 6 , 8 and 9) or at least one port 4 (FIG. 12 ) or functional device 5 (FIG. 13 ), which forms it or integrates it. According to another embodiment, the inherent means of support andreplacement 6 is located on one portion of the surface of the face of thewall 3 of thepouch 2 or at least oneport 4 orfunctional device 5 that forms it or integrates it by then being either located (FIG. 7 ) or distributed over this surface. - According to one embodiment, the inherent means of support and
replacement 6 is located in thelower part 2 b of thepouch unit 1 or in thislower part 2 b and in all or part of themedian part 2 d. - According to one embodiment, quite specially in the case where the
pouch unit 1 is only partially filled, the inherent means of support andreplacement 6 is located in thelower part 2 b of thepouch unit 1 or in thislower part 2 b and all or part of themedian part 2 d. According to another embodiment in the case where thepouch unit 1 is totally filled, the inherent means of support andreplacement 6 can be located in theupper part 2 c of the pouch unit, as is the case if it is located on aport 4 such as theport 4 that is shown inFIG. 12 . - According to possible embodiments, the inherent means of support and
replacement 6 has a surface area for replacement with the contents of thepouch 2 during the process for the production of the biopharmaceutical product P that is larger than, more specially significantly larger than, more specially on the order of a multiple of, the surface area of theinside face 3 b of thewall 3 of thepouch 2 or at least oneport 4 orfunctional device 5 that forms it or integrates it, and that is in direct contact with the contents of thepouch 2. - Such a larger surface area for replacement is obtained as a result of the composition of the inherent means of support and
replacement 6, or thewall 3 of thepouch 2 or at least oneport 4 orfunctional device 5 that forms it or in which it is integrated or the configuration of the inherent means of support andreplacement 6 on thewall 3 of thepouch 2 or at least oneport 4 orfunctional device 5 that forms it or in which it is integrated (FIGS. 8 and 9 ). - According to a functional embodiment, which can be combined with structural embodiments, the inherent means of support and
replacement 6 is active per se, for example, because its nature makes it possible to capture or release the incident body C at any time and permanently, without requiring an action to be taken to do so. - According to another functional embodiment, the inherent means of support and
replacement 6 is not active per se at any time and permanently but it requires being made active as a consequence of a dedicated activation operation. - Such a dedicated activation operation of the inherent means of support and
replacement 6 and the means for its implementation may be the object of different embodiments. - According to one embodiment, the inherent means of support and
replacement 6 is made active in response to the value taken on by at least one physical-biological-chemical condition of the biopharmaceutical product P or at least one physical-biological-chemical condition existing in thepouch 2. Such a physical-biological-chemical condition is, for example, the temperature, the pH, the composition, the contents of a certain body, the presence of a certain microorganism . . . . - According to another embodiment, the inherent means of support and
replacement 6 is made active in response to the value not of the physical-biological-chemical condition as such, but in response to the variation of such a physical-biological-chemical condition. - According to another embodiment, the inherent means of support and
replacement 6 is made active in response to a dedicated activation operation of a physical, biological or chemical nature, such as heat, stirring . . . . - Thus, in these embodiments, means for activating the inherent means of support and
replacement 6 of a physical, biological or chemical nature are provided that are structurally separate from thepouch unit 1 but are designed to be combined functionally with it during the activation of the inherent means of support andreplacement 6. If necessary, these activation means consist of the biopharmaceutical product P that has properties of a physical, biological or chemical nature and that can activate the inherent means of support and replacement. According to the embodiments, these activation means are located outside of thepouch unit 1 or in theinside space 2 a when, for example, they consist of the biopharmaceutical product P. - In the case of
FIG. 3 , the inherent means of support andreplacement 6 is formed by a layer 7 that totally and continuously coats theinside face 3 b of the film of thewall 3 or thewall 3 itself. In such an embodiment, the inherent means of support andreplacement 6 has a surface area for replacement with the biopharmaceutical product P during its production and/or its preservation that is substantially equal to the surface area of theinside face 3 b of thepouch 2 of thepouch unit 1. - In the case of
FIG. 4 , the inherent means of support andreplacement 6 is formed by a continuous coating 8 over the entireinside face 3 b of the film of thewall 3 or thewall 3 itself. - In the case of
FIG. 5 , the inherent means of support andreplacement 6 is formed by a continuous layer 9 that is sandwiched between theoutside face 3 a and theinside face 3 b of the film of thewall 3 or thewall 3 itself, over the entire surface of the film, or the wall. - In the case of
FIG. 6 , the inherent means of support andreplacement 6 is formed by a layer 10 that totally and continuously coats theoutside face 3 a of the film of thewall 3 or thewall 3 itself, with the film of thewall 3 or thewall 3 itself then being able to allow the replacement of the incident body C, in its entire thickness, from theinside space 2 a of thepouch 2 to the outside, and vice versa. - In the case of
FIG. 7 , the inherent means of support andreplacement 6 is formed by a layer 11 that forms a type of part (or “patch”) 11 that locally coats theinside face 3 b of the film of thewall 3 or thewall 3 itself. In this case, either a single such part 11 of suitable surface and shape, located at the desired spot of the film of thewall 3 or thewall 3 itself, or several parts 11, arranged and distributed according to a suitable distribution, can be provided. - In the case of
FIG. 8 , the inherent means of support andreplacement 6 is or comprises a membrane 12 that is more or less an integral part of the film of thewall 3 or thewall 3 itself, on theinside face 3 b. For example, the membrane can be folded in a more or less significant way on itself. - In the case of
FIG. 9 , the inherent means of support andreplacement 6 is formed by crevices 13 or an irregular surface condition with recesses or cavities of the film of thewall 3, obtained by particle bombardment, chemical attack, . . . . In such an embodiment, the inherent means of support andreplacement 6 has, by the very fact of the configuration that is provided thereto, a surface area for replacement with the biopharmaceutical product P during its production that is larger than the surface area of theinside face 3 b of thepouch 2. For example, the inherent means of support andreplacement 6 can have a surface area for replacement on the order of several times, and even a large number of times, the surface area of theinside face 3 b of thepouch 2. - In the case of
FIG. 10 , the inherent means of support andreplacement 6 is a solid body 14, for example carried by the film of thewall 3 or by thewall 3 itself, over or toward theinside face 3 b. In such an embodiment, the inherent means of support andreplacement 6 has, in itself, a surface area for replacement with the biopharmaceutical product P during its production that is larger than the surface area of theinside face 3 b of thepouch 2. For example, themeans 6 can have a surface area for replacement on the order of several times, and even a large number of times, the surface area of theinside face 3 b of thepouch 2. - In the case of
FIG. 11 , the inherent means of support andreplacement 6 consists of a compartment 15 that is limited by awall 16 that makes possible the replacement between the inside and the outside of thecompartment 16. As above, the inherent means of support andreplacement 6 occupies the entire surface or only a portion of the surface of the film of thewall 3 or by thewall 3 itself by being either located or distributed relative to this surface. - In the case of
FIG. 12 , the inherent means of support andreplacement 6 is formed by or integrated in aport 4, while being, as above, able to be accessible from theinside space 2 a of thepouch 2 and in direct physical contact with the contents of thepouch 2. This embodiment includes the case where the inherent means of support andreplacement 6 is formed by or integrated not directly in theport 4 itself, but indirectly, namely in an element for supporting theport 4. - In the case of
FIG. 13 , the inherent means of support andreplacement 6 is formed by or integrated in afunctional device 5, while being, as above, able to be accessible from theinside space 2 a of thepouch 2 and in direct physical contact with the contents of thepouch 2. This embodiment includes the case where the inherent means of support andreplacement 6 is formed by or integrated not directly in thefunctional device 5 itself, but indirectly, namely in an element for supporting thefunctional device 5. - Of course, different structural embodiments of those described above can be combined with one another, either for the same incident body C or for different incident bodies C.
- The process for production and the
pouch unit 1 can be the object of several different embodiments relative to the time when the inherent means of support andreplacement 6 is loaded with the incident body C and the time when it is not loaded with the incident body C, relative to the time before the filling of thepouch 2 and once the biopharmaceutical product P is produced. - In one embodiment, before filling with contents, the inherent means of support and
replacement 6 is not loaded with the incident body C. - In another embodiment, before filling with contents, the inherent means of support and
replacement 6 is substantially loaded with the incident body C. - In one embodiment, after the biopharmaceutical product P has been produced, the inherent means of support and
replacement 6 is not loaded with the incident body C. - In another embodiment, after the biopharmaceutical product P has been produced, the inherent means of support and
replacement 6 is substantially loaded with the incident body C. - These embodiments are combined with one another for the same inherent means of support and
replacement 6 and the same incident body C. - Thus, before filling the
pouch 2, the inherent means of support andreplacement 6 is not loaded with the incident body C, and after the biopharmaceutical product P has been produced, in contrast, it is loaded with the incident body C. This embodiment is applied, for example, with an incident body C that is an undesirable body that does not exist at the beginning of the process for the production of the biopharmaceutical product P, but is produced during this production process and that is desired to be eliminated within the biopharmaceutical product P itself. - In another embodiment, before filling the
pouch 2, the inherent means of support andreplacement 6 is substantially loaded with the incident body C, and after the biopharmaceutical product P has been produced, in contrast, it is not loaded with the incident body C. This embodiment that is applied, for example, with a body C can then be an incident body that is necessary to the process for the production of the biopharmaceutical product P, existing at the beginning of the production process, consumed during this process, and not existing at the end.
Claims (19)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0956889A FR2950802B1 (en) | 2009-10-02 | 2009-10-02 | ELABORATION AND / OR PRESERVATION OF A BIOPHARMACEUTICAL PRODUCT. |
FR0956889 | 2009-10-02 | ||
PCT/FR2010/052048 WO2011039472A2 (en) | 2009-10-02 | 2010-09-29 | Production of a biopharmaceutical product |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120193264A1 true US20120193264A1 (en) | 2012-08-02 |
Family
ID=42274539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/499,738 Abandoned US20120193264A1 (en) | 2009-10-02 | 2010-09-29 | Production of a biopharmaceutical product |
Country Status (4)
Country | Link |
---|---|
US (1) | US20120193264A1 (en) |
EP (1) | EP2483385A2 (en) |
FR (1) | FR2950802B1 (en) |
WO (1) | WO2011039472A2 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5714384A (en) * | 1994-06-28 | 1998-02-03 | Wilson; John R. | Compartmentalized tissue culture bag |
US5988422A (en) * | 1998-07-16 | 1999-11-23 | Stedim, Z.I. Des Paluds | Sachets for bio-pharmaceutical fluid products |
US20040209360A1 (en) * | 2003-04-18 | 2004-10-21 | Keith Steven C. | PVA-based polymer coating for cell culture |
US20050186669A1 (en) * | 2004-02-20 | 2005-08-25 | Cesco Bioengineering Co., Ltd. | Apparatus and method for preparing and culturing cells |
US20050239200A1 (en) * | 2004-04-23 | 2005-10-27 | Beckwith Scott W | Devices for culturing anaerobic microorganisms and methods of using the same |
US20060240458A1 (en) * | 2005-04-04 | 2006-10-26 | Steichen John C | Flexible culture medium bag containing nutrient concentrate |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4557723A (en) | 1983-08-18 | 1985-12-10 | Drug Delivery Systems Inc. | Applicator for the non-invasive transcutaneous delivery of medicament |
US4638043A (en) | 1984-11-13 | 1987-01-20 | Thermedics, Inc. | Drug release system |
US4752478A (en) | 1984-12-17 | 1988-06-21 | Merck & Co., Inc. | Transdermal system for timolol |
AU609769B2 (en) | 1987-02-10 | 1991-05-09 | Drug Delivery Systems Inc. | Electrolytic transdermal delivery of proteins |
FR2767141B1 (en) * | 1997-08-08 | 2001-05-11 | Sanofi Elf | DEVICE FOR THE CULTURE OF LACTIC BACTERIA |
FR2795647B1 (en) * | 1999-06-30 | 2004-05-07 | Maco Pharma Sa | POCKET ASSEMBLY FOR RECEIVING BIOLOGICAL FLUID AND HIGHLIGHTING POSSIBLE BIOLOGICAL FLUID CONTAMINATION |
DE19932439C2 (en) * | 1999-07-12 | 2002-06-13 | Sefar Ag Rueschlikon | bioreactor |
DE10010950A1 (en) * | 2000-03-06 | 2001-09-20 | Sefar Ag Rueschlikon | Disposable bioreactor for cultivation of dendritic cells used in immuno therapy, comprises a substrate-carrying organic material located in a pouch |
JP2002112763A (en) * | 2000-10-10 | 2002-04-16 | Nipro Corp | Cell culture container |
US20050205840A1 (en) * | 2003-10-03 | 2005-09-22 | Farneth William E | Oxygen scavenging compositions and methods of use |
CA2552717C (en) * | 2004-01-07 | 2011-11-29 | Levtech, Inc. | Mixing bag with integral sparger and sensor receiver |
DK1773976T4 (en) * | 2004-06-04 | 2020-02-10 | Global Life Sciences Solutions Usa Llc | SINGLE-BORE ACTOR SYSTEMS AND PROCEDURES |
AU2007226945B2 (en) * | 2006-03-20 | 2011-09-01 | Gusmer Enterprises, Inc. | Sustained release additives for fermentation products |
GB0700380D0 (en) * | 2007-01-09 | 2007-02-14 | Breath Ltd | Storage Of Ampoules |
JP5209433B2 (en) | 2007-10-19 | 2013-06-12 | 日東電工株式会社 | Patch preparation |
-
2009
- 2009-10-02 FR FR0956889A patent/FR2950802B1/en active Active
-
2010
- 2010-09-29 EP EP10773658A patent/EP2483385A2/en not_active Withdrawn
- 2010-09-29 WO PCT/FR2010/052048 patent/WO2011039472A2/en active Application Filing
- 2010-09-29 US US13/499,738 patent/US20120193264A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5714384A (en) * | 1994-06-28 | 1998-02-03 | Wilson; John R. | Compartmentalized tissue culture bag |
US5988422A (en) * | 1998-07-16 | 1999-11-23 | Stedim, Z.I. Des Paluds | Sachets for bio-pharmaceutical fluid products |
US20040209360A1 (en) * | 2003-04-18 | 2004-10-21 | Keith Steven C. | PVA-based polymer coating for cell culture |
US20050186669A1 (en) * | 2004-02-20 | 2005-08-25 | Cesco Bioengineering Co., Ltd. | Apparatus and method for preparing and culturing cells |
US20050239200A1 (en) * | 2004-04-23 | 2005-10-27 | Beckwith Scott W | Devices for culturing anaerobic microorganisms and methods of using the same |
US20060240458A1 (en) * | 2005-04-04 | 2006-10-26 | Steichen John C | Flexible culture medium bag containing nutrient concentrate |
Also Published As
Publication number | Publication date |
---|---|
FR2950802B1 (en) | 2012-02-03 |
FR2950802A1 (en) | 2011-04-08 |
WO2011039472A2 (en) | 2011-04-07 |
WO2011039472A3 (en) | 2012-03-22 |
EP2483385A2 (en) | 2012-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Motedayen et al. | Development and characterisation of composite films made of kefiran and starch | |
US8877469B2 (en) | Method of drying biological material | |
Yan et al. | Effects of extrusion and glycerol content on properties of oxidized and acetylated corn starch-based films | |
CA2673589C (en) | Method of drying biological material | |
JP5344094B2 (en) | Multilayer film and cell culture vessel | |
Moreira et al. | Electrospun polymeric nanofibers in food packaging | |
US20210277380A1 (en) | Aggregate of cell carrier particles and method for preparing same | |
AU2015229296A1 (en) | In vivo and in vitro use of graphene | |
JP2005323588A (en) | Culturing double vessel and culturing method | |
CN108913529A (en) | Product comprising lactic acid bacteria and desiccant | |
JP2022540419A (en) | Methods of loading microorganisms into multiphase biomaterials | |
WO2007056355A3 (en) | Devices and methods for culturing, preserving, transporting, storing, reconstituting and assaying cellular materials | |
WO2009088023A1 (en) | Culture bag and cell culture method | |
US20120193264A1 (en) | Production of a biopharmaceutical product | |
US20210269210A1 (en) | Environment protected starch container device | |
JP2016513606A (en) | Ethyl alcohol release package for baked foods | |
JP6844260B2 (en) | Culture container and method for manufacturing the culture container | |
KR20150089904A (en) | manufacturing method of antibacterial food paper using bactoster alexin and antibacterial food paper thereby | |
FR3032718A1 (en) | MICROBIAL CULTURE METHOD USING AN ANALYTICAL BAG COMPRISING CULTURE BROTH POWDER | |
JP2006042810A (en) | Method for producing ultrathin type multiwell plate | |
JP6241257B2 (en) | Cultivation container and lymphocyte culture method | |
Du et al. | Porous sepiolite/starch composites: Preparation, structure and absorption properties | |
Kim et al. | A long-term storable gel-laden chip composite built in a multi-well plate enabling in situ cell encapsulation for high-throughput liver model | |
TW201213206A (en) | A biodegradable mixture | |
GB2582174A (en) | Environment protected starch container device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SARTORIUS STEDIM BIOTECH S.A., FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARBAROUX, MAGALI;DOREY, SAMUEL;GUENERON, MAREVA;AND OTHERS;SIGNING DATES FROM 20120323 TO 20120326;REEL/FRAME:027970/0987 |
|
AS | Assignment |
Owner name: SARTORIUS STEDIM FMT SAS, FRANCE Free format text: MERGER;ASSIGNOR:SARTORIUS STEDIM BIOTECH;REEL/FRAME:031974/0578 Effective date: 20131025 |
|
AS | Assignment |
Owner name: SARTORIUS STEDIM FMT SAS, FRANCE Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED ON REEL 031974 FRAME 0578. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER;ASSIGNOR:SARTORIUS STEDIM BIOTECH;REEL/FRAME:032086/0293 Effective date: 20131025 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |